WARSAW — Zimmer Biomet Holdings Inc., a global leader in musculoskeletal healthcare, has announced that it has secured an exclusive global distribution agreement with CelgenTek Innovations Corporation, which includes its N-Force Fixation System and iN3 Cement.

This innovative bone void-filling solution allows healthcare professionals to directly administer Zimmer Biomet’s N-Force Blue­­­­­­-Bone Substitute Material and CelgenTek’s iN3 Cement directly through a fenestrated screw in a single integrated construct. The financial terms of the transaction were not disclosed.

CelgenTek Innovations, comprised of subsidiaries InnoVision Inc., Memphis, Tenn., and CelgenTek LTD, Shannon, Ireland, designs and manufactures the N-Force Fixation System and iN3 Cement. The N-Force Fixation System is an augmented fixation system cleared in the U.S. and EU and the iN3 is a pre-mix calcium phosphate cement available in the EU.

“The driving focus of Zimmer Biomet’s trauma portfolio has always been to equip surgeons with exceptional tools that can unlock personalized outcomes for patients, whether they are suffering from routine or complex fracture injuries, which is exactly why we have chosen to pursue this partnership with CelgenTek Innovations,” said Randy S. Sessler, vice president and general manager of the global trauma business. “The combination of the N-Force Fixation System with our N-Force Blue BSM represents ingenuity and stability in an innovative design, and we are excited to include these clinical solutions as part of our focused strategy to serve trauma surgeons and healthcare systems around the globe.”

The N-Force Fixation System is an augmented fracture fixation system comprised of fenestrated screws, washers and the N-Force Blue-Bone­­ Substitute material. The bone substitute material is injected directly through the fenestrated screw, providing not only fixation, but also serving as the delivery system for filling the void.

Because defects are filled after reduction, the screws can be placed precisely in the desired location. The system is designed to help more fully fill the bone void and enhance structural support of the implant.

“We are honored to partner with Zimmer Biomet in expanding the reach and influence of our orthobiologic portfolio with the commercial capabilities of an innovation leader in global musculoskeletal healthcare,” said Thomas A. Russell, M.D., CEO, CelgenTek Innovations. “CelgenTek Innovations is positioned at the forefront of clinical innovation in the United States, Europe and Australia and in partnership with Zimmer Biomet we aim to accelerate our strategies for ongoing growth.”